Related Experiment Videos
The impact of introducing combined first-trimester trisomy 21 screening in the French population
1Agence de la biomédecine, Saint-Denis la Plaine, 93 212, France dominique.royere@biomedecine.fr.
Insights
France
Area of Science:
- Prenatal screening and diagnostics
- Maternal-fetal medicine
- Public health policy
Background:
- France has a long history of state-funded prenatal screening for trisomy 21.
- National implementation of first-trimester combined screening occurred in 2010.
Purpose of the Study:
- To assess the impact of the national first-trimester trisomy 21 screening policy.
- To evaluate the reduction in invasive prenatal diagnostic procedures.
Main Methods:
- Analysis of national screening and diagnostic procedure data from 2009-2012.
- Calculation of screen-positive rates, positive predictive values, and prenatal diagnosis rates.
Main Results:
- First-trimester screening became dominant (70% by 2012).
- Screen-positive rates dropped significantly (9.5% to 4.8%).
- Invasive procedures decreased by 47%, while prenatal diagnoses increased by 2.7%.
Conclusions:
- Shifting to first-trimester screening effectively reduced invasive testing.
- This policy change maintained high rates of prenatal trisomy 21 diagnosis.
Background:
French state health insurance has funded trisomy 21 prenatal screening for all pregnant women since decades. First-trimester combined screening was introduced nationally and funded in 2010.
Objective:
To evaluate the impact of the introduction, of a national policy of prenatal trisomy 21 first-trimester screening on the reduction of invasive prenatal diagnostic procedures.
Methods:
The results of all prenatal trisomy 21 screening and invasive diagnostic procedures were collected for the whole country over the period 2009-12. The screen-positive rates (risk cut-off 1 : 250, including isolated nuchal translucency ≥ 3.5 mm), positive predictive values and percentage of cases diagnosed prenatally were calculated.
Results:
Over the study period the number of women undergoing serum screening (including first- and second-trimester screening tests) increased from 678 803 to 689 651 (83 to 85% of deliveries, P < 0.0001). By 2012, first-trimester combined screening accounted for 70% of all trisomy 21 screening. The screen-positive rate decreased from 9.5 to 4.8% (P < 0.001) resulting in a 37 478 (47%) drop (P < 0.001) in the number of invasive diagnostic procedures. The positive predictive value of screening increased from 2.6 to 6.1% from 2009 to 2012 (P < 0.001), due to the higher positive predictive value of first-trimester over second-trimester screening (9.1 vs. 1.8% over the period 2010-12, P < 0.001). The percentage of prenatally diagnosed cases remained high at around 80% between 2010 and 2012.
Conclusions:
The policy shift from second-trimester to first-trimester trisomy 21 screening allowed to reduce the number of invasive tests. The number of antenatal trisomy 21 diagnoses increased (+2.7%) over the study period.